1.860.908.4133
info@resourcesunlimitedllc.com
1905 Audubon Ct.
Spokane, WA 99224
Menu

Category: Uncategorized

07-24-2018 – ETBI – EastGate Biotech Provides Update on Investment From Genluiching Mining Corporation

July 25, 2018
| No Comments
| Categories: Uncategorized

EastGate to Receive the First Non-dilutive Investment Tranch from the Total Funding up to $5 million USD as per the Terms of the Definitive Agreement WEST CALDWELL, NJ and TORONTO, ON / ACCESSWIRE / July 24, 2018 / EastGate Biotech Corp. (OTC PINK: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of type 2 diabetes, announced that it is to receive the first tranch of the investment from Genluiching Mining Corporation as per the definitive agreement signed in April. As per the previously announced executed Definitive Agreement, Genluiching Mining will invest...

Read More

07-23-2018 – TNTY – True Nature Holding Establishes “Apps for Better Living” Curator Process

July 25, 2018
| No Comments
| Categories: Uncategorized

ATLANTA, July 23, 2018 (GLOBE NEWSWIRE) -- True Nature Holding, Inc. (OTCQB:TNTY) (the "Company" or "True Nature") today announced its own initiative to improve healthcare outcomes and lifestyle for individuals and their pets by establishing a new app library and listing service. “Apps for Better Living” (www.appsforbetterliving.com) will include a wide range of applications aimed at helping individuals take control of their heath and make better lifestyle choices. The library will include any and all apps from developers who apply, after vetting for integrity, including those for pets, and individuals. A separate section of the web site will focus on...

Read More

06-21-2018 – ETBI – EastGate Biotech Unveils Manufacturing Plans in an MOU with Mystic Pharmaceuticals Limited for Its Liquid Insulin Mouth Rinse Solution

July 16, 2018
| No Comments
| Categories: Uncategorized

WEST CALDWELL, NJ and TORONTO, ON / ACCESSWIRE / June 21, 2018 / EastGate Biotech Corp. (OTC PINK: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of Type 2 diabetes, announced it entered into a Memorandum of Understanding (MOU) with Mystic Pharmaceuticals Limited (www.mysticpharma.info) of Bangladesh. The scope of the MOU is to focus on the manufacturing of the company's liquid insulin mouth rinse solution for specific markets. Presently, EastGate is developing its insulin mouth rinse in the Philippines, Pakistan, and Europe through its JV with Nico Innovapharma. The terms of...

Read More

06-19-2018 – ETBI – EastGate Biotech Strikes Investment and Licensing Collaboration with Nico Innovapharma for Liquid Insulin Mouth Rinse Solution for the European Market

July 16, 2018
| No Comments
| Categories: Uncategorized

Investment and Product License Includes Licensing Fee and Development Costs WEST CALDWELL, NJ and TORONTO, ON / ACCESSWIRE / June 19, 2018 / EastGate Biotech Corp. (OTC PINK: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of Type 2 diabetes, announced it entered into a binding Memorandum of Understanding (MOU) with Nico Innovapharma (www.nicoinnovagroup.com) (www.nilamedica.com), an innovative start up under incorporation, with its principal headquarters in Brescia, Italy. The scope of the MOU is for the licensing of the company's liquid insulin mouth rinse solution. The terms of the MOU detail...

Read More

06-09-2018 – TPIV – TapImmune Announces Pricing of $70 Million Private Placement

July 16, 2018
| No Comments
| Categories: Uncategorized

Financing Led by New Enterprise Associates (NEA) Financing to Close Concurrently with Close of Merger with Marker Therapeutics JACKSONVILLE, Florida, June 8, 2018 – TapImmune Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company, today announced that it has entered into security purchase agreements with certain institutional and accredited investors in connection with a private placement of its equity securities.  The private placement will be led by New Enterprise Associates (NEA) with participation from Aisling Capital and Perceptive Advisors, among other new and existing investors.  The private placement is expected to be completed concurrently with the closing of the proposed merger between TapImmune Inc....

Read More

03-08-2018 – DATI – OpenVision Labs Launches New Media Player to Support Independent Film Makers in Partnership with Hollywood Actor, Adam Beach

March 11, 2018
| No Comments
| Categories: Uncategorized

New York, NY , March 08, 2018 (GLOBE NEWSWIRE) -- OpenVision Labs, a New York-based digital communications and live-streaming solutions provider, recently launched its OpenVision Media Player platform with pay-per-view functionality to support an independent film making initiative headed by “Suicide Squad”, actor, Adam Beach; releasing “The Watchman’s Canoe” In partnership with accomplished actor, Adam Beach, of “Law & Order: Special Victims Unit”, “Joe Dirt,” and “Windtalkers,” among many others, OpenVision Labs has released Mr. Beach’s first independent film on its proprietary, pay-per-view, OpenVision Media Player. “We are very excited to have partnered with the innovative team at OpenVision Labs...

Read More

03-05-2018 – ETBI – EastGate Biotech Announces Licensing/Distribution MOU With BuPharco for the Insulin Mouth Rinse in the Philippines for Type 2 Diabetes Patients

March 11, 2018
| No Comments
| Categories: Uncategorized

WEST CALDWELL, NJ and TORONTO, ON / ACCESSWIRE / March 5, 2018 / EastGate Biotech Corp. (OTC PINK: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of type 2 diabetes. We are thrilled to announce today that EastGate has signed a Memorandum of Understanding (MOU) with Bukidnon Pharmaceutical Multi-Purpose Cooperatives (BuPharco). The MOU outlines the strategic plan to commercialize the oral insulin mouth rinse delivered through the buccal mucosa (inner lining of mouth) and penetrates the blood brain barrier. BuPharco will initially compile, submit, and file all dossiers to the FDA...

Read More

03-01-2018 – ETBI – Eastgate Biotech Provides Corporate Update

March 11, 2018
| No Comments
| Categories: Uncategorized

WEST CALDWELL, NJ and TORONTO, ON / ACCESSWIRE / March 1, 2018 / EastGate Biotech Corp. (OTC PINK: ETBI), an emerging pharmaceutical company that focuses on innovative pharmaceutical developments and produces and distributes innovative and healthy nutraceuticals based on natural therapies has announced today its corporate update. EastGate Biotech is pleased to provide its shareholders with the following corporate update: The Company's strategic moves over the past year to improve its underlying operations were part of a corporate vision to be a "disrupter" in the drug delivery sector targeting unmet medical needs. As a company, we collectively agreed that drug development...

Read More

02-27-2018 – DATI – Digital Arts Media Network to Acquire Stake in ‘Reg CF’ Crowd Funding Portal; Expanding Accelerated Capital Formation Programs

March 11, 2018
| No Comments
| Categories: Uncategorized

NEW YORK, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Digital Arts Media Network, Inc.  (OTCMKTS:DATI), a specialized tech accelerator leveraging the Public Accelerator-Incubator (PAI) model, announced today that the Company is in talks to acquire a strategic stake in a SEC registered and FINRA member, crowdfunding portal, where both accredited and non-accredited investors can invest in high-growth high-tech startup businesses. “Several meetings with a number of companies and investors in the blockchain / crypto space, caused us to rethink the ‘why’ in our pursuit of aligning DATI with a FINRA approved crowd funding portal; then to justify those means with the ‘how,’” said...

Read More

02-14-2018 – INTV – Integrated Ventures Reports Q2 Financial Results Including $105,088 Of Crypto Mining Revenues

March 11, 2018
| No Comments
| Categories: Uncategorized

PHILADELPHIA, Feb. 14, 2018 /PRNewswire/ -- Integrated Ventures Inc. (OTCQB: INTV)("Company") today reported the filing with the SEC, of its Quarterly Report (Form 10-Q), for its Second Quarter, ended December 31, 2017, with an official release scheduled for 10AM. During the three months ended December 31, 2017, the Company reported revenues totaling $105,088, consisting of $59,498 in mining fees and $45,590 in mining equipment sales. The cost of revenues was $46,818, resulting in a gross profit of $58,270 and profit margins of 55%. "The Company had successfully launched operations and received revenues from sales of mining equipment and from operating two cryptocurrency mining locations in Pennsylvania. As we have entered 2018 with a solid cash position, zero convertible...

Read More